TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35168969

Group type: EXPERIMENTAL
Intervention: Multifaceted training programme (two 4-hour training sessions, dissemination of interactive educational materials, review of video-recorded consultations, individual feedback)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multifaceted training programme
Number of subjects: 100
Study: 34407339

Group type: EXPERIMENTAL
Intervention: Convalescent plasma with a high titer of antibodies against SARS-CoV-2
Number of subjects: 511

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 511
Study: 32079885

Group type: EXPERIMENTAL
Intervention: Volar plate fixation
Number of subjects: 90
Study: 34920097

Group type: EXPERIMENTAL
Intervention: OC‐01 0.03 mg
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: OC‐01 0.06 mg
Number of subjects: 123

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 123
Study: 33909728

Group type: EXPERIMENTAL
Intervention: Rough-surface implants
Number of subjects: 114

Group type: COMPARATOR
Intervention: Machined implants
Number of subjects: 114

Group type: COMPARATOR
Intervention: Nobel Biocare implants
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sweden & Martina implants
Number of subjects: 114
Study: 33607371

Group type: EXPERIMENTAL
Intervention: Posterior rhabdosphincter reconstruction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard reconstruction technique
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 40
Study: 32030723

Group type: EXPERIMENTAL
Intervention: Microwave therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 11
Study: 36972981

Group type: EXPERIMENTAL
Intervention: Supramaximal high-intensity interval training (HIT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Moderate-intensity training (MIT)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both HIT and MIT
Number of subjects: 68
Study: 34620312

Group type: EXPERIMENTAL
Intervention: High fiber rye products
Number of subjects: 242

Group type: COMPARATOR
Intervention: Refined wheat products
Number of subjects: 242
Study: 32526210

Group type: EXPERIMENTAL
Intervention: Pharmacist-led care group
Number of subjects: 2718

Group type: COMPARATOR
Intervention: Conventional care group
Number of subjects: 2718
Study: 35051870

Group type: EXPERIMENTAL
Intervention: Branching simulations intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 34588162

Group type: EXPERIMENTAL
Intervention: Early CT coronary angiography
Number of subjects: 1748

Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 1748
Study: 34989181

Group type: EXPERIMENTAL
Intervention: Simulator training for knee arthrocentesis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Simulator training for shoulder arthrocentesis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Simulator training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Theoretical knowledge and confidence assessment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Theoretical knowledge assessment
Number of subjects: 30
Study: 32474602

Group type: EXPERIMENTAL
Intervention: GBLUP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ANN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GBLUP-D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SVM
Number of subjects: 0
Study: 35998839

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT) alone
Number of subjects: 467

Group type: COMPARATOR
Intervention: Adjuvant chemoradiotherapy (CRT)
Number of subjects: 467
Study: 33775745

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 115
Study: 35476681

Group type: EXPERIMENTAL
Intervention: TRIANGLE intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: TRIANGLE intervention (per-protocol subgroup)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: TRIANGLE app usage
Number of subjects: 66
Study: 33453703

Group type: EXPERIMENTAL
Intervention: Chest echography
Number of subjects: 0
Study: 35005065

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN‐DBS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN‐DBS) with multiple microelectrode recordings
Number of subjects: 0
Study: 35487183

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36403344

Group type: EXPERIMENTAL
Intervention: Mat Pilates
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Belly Dance
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (Educational Sessions)
Number of subjects: 74
Study: 33928660

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32527251

Group type: EXPERIMENTAL
Intervention: Web-based physical activity program
Number of subjects: 266
Study: 34224503

Group type: EXPERIMENTAL
Intervention: Universidade do Bebê (UBB)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 484
Study: 32285847

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Conscious sedation
Number of subjects: 150
Study: 32175908

Group type: EXPERIMENTAL
Intervention: capABILITY app with trigger messages (spark and facilitator messages)
Number of subjects: 20

Group type: COMPARATOR
Intervention: capABILITY app alone (control condition)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: capABILITY app for high and midusers (n=14)
Number of subjects: 20
Study: 35283720

Group type: EXPERIMENTAL
Intervention: Mailing of urine self-sampling kit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mailing of vaginal self-sampling kit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional invitation letter (control)
Number of subjects: 0
Study: 33063882

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 100
Study: 35748937

Group type: EXPERIMENTAL
Intervention: Parent training intervention
Number of subjects: 160
Study: 32627592

Group type: EXPERIMENTAL
Intervention: Baby CHAT intervention
Number of subjects: 20
Study: 36153281

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study: 33468144

Group type: EXPERIMENTAL
Intervention: Transition education program
Number of subjects: 200

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 200
Study: 35063230

Group type: EXPERIMENTAL
Intervention: Folic acid consumption (measured as Dietary Folate Equivalents - DFE)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Flour intake
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Presence of at least one more child under 5 years of age
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Receiving the Bolsa Família Program
Number of subjects: 101
Study: 32367201

Group type: EXPERIMENTAL
Intervention: TiN-coated CoCrMo TKA
Number of subjects: 101

Group type: COMPARATOR
Intervention: Uncoated CoCrMo TKA
Number of subjects: 101
Study: 32503365

Group type: EXPERIMENTAL
Intervention: Stress management counseling (individual sessions, four sessions, twice a week at 35 and 36 weeks of gestation)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Routine cares (control group)
Number of subjects: 46
Study: 36481243

Group type: EXPERIMENTAL
Intervention: Smart Beginnings intervention
Number of subjects: 403
Study: 33682268

Group type: COMPARATOR
Intervention: Conventional needle irrigation with 4% NaOCl (Group 1, n=15)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: EndoActivator with 4% NaOCl (Group 2, n=19)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: XP‐endo Finisher with 4% NaOCl (Group 3, n=17)
Number of subjects: 74
Study: 35092868

Group type: EXPERIMENTAL
Intervention: HDRS Early Insomnia items
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HDRS Late Insomnia items
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HDRS Middle Insomnia items
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HDRS Global Insomnia score
Number of subjects: 80
Study: 33705452

Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Positive influenza POCT result
Number of subjects: 648
Study: 36034548

Group type: EXPERIMENTAL
Intervention: Iron supplementation for 3 months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Iron supplementation for 6 months
Number of subjects: 80
Study: 36098670

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (24, 48, and 72 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 33300448

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention group (n = 35)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (n = 36)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Proxy reports from parents in VR group (n = 35)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Proxy reports from parents in control group (n = 36)
Number of subjects: 71
Study: 33198689

Group type: EXPERIMENTAL
Intervention: Theory-informed and user-centered information campaign including posters, leaflets, adverts, and films displayed in various media.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theory-informed and user-centered information campaign.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control county (no campaign).
Number of subjects: 0
Study: 35738644

Group type: EXPERIMENTAL
Intervention: RehaCAT+ (web-based computer-adaptive patient-reported outcome test platform)
Number of subjects: 1848

Group type: COMPARATOR
Intervention: RehaCAT (standard diagnostic system)
Number of subjects: 1848
Study: 33039853

Group type: EXPERIMENTAL
Intervention: Standard Therapy + Expiratory Flow Acceleration (EFA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard Therapy (ST)
Number of subjects: 25
Study: 36114808

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 17
Study: 32031466

Group type: EXPERIMENTAL
Intervention: Modified‐Krishnan’s frailty index (FI)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: CSHA frailty index (FI)
Number of subjects: 130
Study: 34843078

Group type: COMPARATOR
Intervention: Sufentanil (0.1 ug/kg) combined with propofol
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.1 mg/kg) combined with propofol
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Both groups (Sufentanil and Nalbuphine)
Number of subjects: 224
Study: 35949399

Group type: EXPERIMENTAL
Intervention: PCR arm (ethambutol discontinued if no resistance detected)
Number of subjects: 203

Group type: COMPARATOR
Intervention: C arm (standard 4-drug combination pending phenotypic results)
Number of subjects: 203
Study: 33331917

Group type: COMPARATOR
Intervention: Plasma Aβ42/40 ratio greater than 0.107
Number of subjects: 483
Study: 35575454

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided suprascapular nerve blocks with ropivacaine 5 mL 2 mg/mL
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ultrasound-guided injections of 5 mL sterile saline solution (NaCl 0.9%)
Number of subjects: 35
Study: 34753541

Group type: EXPERIMENTAL
Intervention: Probiotics combined with ABA intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: ABA intervention alone (Control)
Number of subjects: 41
Study: 33185374

Group type: EXPERIMENTAL
Intervention: Epidural saline injection while supine (A group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Epidural saline injection in sitting position (B group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison between groups A and B
Number of subjects: 44
Study: 33340285

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 33666540

Group type: EXPERIMENTAL
Intervention: TP 3‐in‐1™ juice (n = 16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 31
Study: 35141485

Group type: EXPERIMENTAL
Intervention: AFO with plantar flexion stop (AFO‐PlfS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AFO with plantar flexion resistance (AFO‐PlfR)
Number of subjects: 20
Study: 36426764

Group type: EXPERIMENTAL
Intervention: Wondaleaf female condom
Number of subjects: 220

Group type: COMPARATOR
Intervention: FC2 female condom
Number of subjects: 220
Study: 35210180

Group type: EXPERIMENTAL
Intervention: Low-intensity continuous training
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (Sedentary group)
Number of subjects: 48
Study: 35881420

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (fosinopril or hydrochlorothiazide alone or combined with a statin)
Number of subjects: 470
Study: 33404758

Group type: EXPERIMENTAL
Intervention: Milk supplemented with 107 CFU/mL of Lactobacillus rhamnosus SP1
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard milk (Control)
Number of subjects: 42
Study: 32119192

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 33342316

Group type: EXPERIMENTAL
Intervention: Ingestion-time hypertension trials following minimum guidelines for treatment timing based on internal biological time (morning vs evening) and assessed using ABPM.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABPM as the primary or sole method of BP assessment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimum required features for analysis of ABPM-determined 24 h BP pattern including asleep BP mean and sleep-time relative BP decline.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABPM performed with validated devices at least hourly throughout two or more consecutive 24 h periods.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calculation of minimum required sample size using proper statistical methods.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypertension chronopharmacology and chronotherapy trials should preferably be randomized double-blind, randomized open-label with blinded-endpoint, or crossover in design.
Number of subjects: 0
Study: 33059620

Group type: EXPERIMENTAL
Intervention: QFT conversion using manufacturers' definition (def1)
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: QFT conversion using stricter definition (def2)
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: QFT conversion using stricter definition (def3)
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: QFT conversion using stricter definition (def4)
Number of subjects: 2187

Group type: COMPARATOR
Intervention: Comparison of HIV positive not on antiretroviral treatment to HIV negative using def1
Number of subjects: 2187
Study: 33038532

Group type: EXPERIMENTAL
Intervention: KH‐ePVS
Number of subjects: 6373

Group type: EXPERIMENTAL
Intervention: Duarte‐ePV
Number of subjects: 6373
Study: 32408868

Group type: EXPERIMENTAL
Intervention: Iyengar-based yoga intervention (twice weekly group classes and once weekly home practice for 12 weeks)
Number of subjects: 27
Study: 35509178

Group type: EXPERIMENTAL
Intervention: Gadolinium-based contrast agents
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Nomogram prediction model
Number of subjects: 1404
Study: 34797962

Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide (IDegLira)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Insulin degludec
Number of subjects: 720

Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 720
Study: 32876755

Group type: EXPERIMENTAL
Intervention: SAP P11-4 (Curodont Repair, Windisch, Switzerland) applied and stored for 24 hours in artificial saliva
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SAP P11-4 applied
Number of subjects: 45

Group type: COMPARATOR
Intervention: No pretreatment with SAP P11-4 (control group)
Number of subjects: 45
Study: 36053298

Group type: EXPERIMENTAL
Intervention: Oral OXT (24 IU)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intranasal OXT
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 35238791

Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA) combined with machine learning methods
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Machine learning classifiers using EMA data
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Machine learning methods
Number of subjects: 45
Study: 34328570

Group type: EXPERIMENTAL
Intervention: BI plus CETA
Number of subjects: 160

Group type: COMPARATOR
Intervention: BI alone
Number of subjects: 160
Study: 33164692

Group type: EXPERIMENTAL
Intervention: Del Nido cardioplegia
Number of subjects: 100

Group type: COMPARATOR
Intervention: BSTH cardioplegia
Number of subjects: 100
Study: 34087678

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) during exercise
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham ventilation
Number of subjects: 14
Study: 32170259

Group type: EXPERIMENTAL
Intervention: Blended learning approach based on an e-learning resource
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group with no prior teaching
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Blended learning approach
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 615916337

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 33

Group type: COMPARATOR
Intervention: Laser
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: No morphological abnormalities
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: External limiting membrane disruption
Number of subjects: 33
Study: 36227461

Group type: EXPERIMENTAL
Intervention: VT substrate ablation (ABLATE arm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical treatment (OMT arm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CMR-guided ablation
Number of subjects: 0
Study: 33357480

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance (15 mg per day for platelets >100×10^9 cells/L or 10 mg per day for platelets 60-100×10^9 cells/L, days 1-21 every 28 days) for 24 months
Number of subjects: 300

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance
Number of subjects: 300
Study: 32988822

Group type: EXPERIMENTAL
Intervention: Continuous Infusion (CI) of cloxacillin (two 75-mg/kg 12-h infusions per day for 3 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intermittent Infusion (ItI) of cloxacillin (four 37.5-mg/kg 1-h infusions per day for 3 days)
Number of subjects: 11
Study: 35759680

Group type: EXPERIMENTAL
Intervention: 6‐days clotrimazole 2% vaginal cream once‐daily plus 15‐days concomitant acid pH thymol and zinc‐containing cleansing wash (SaugellaActi3) twice‐daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: 6‐days clotrimazole treatment alone
Number of subjects: 200
Study: 34493259

Group type: EXPERIMENTAL
Intervention: Family-based intervention using motivational interviewing and principles of cognitive‐behavioral therapy
Number of subjects: 928

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 928
Study: 33142988

Group type: EXPERIMENTAL
Intervention: Exposure to commercial messages advertising food products
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Sugared cereals (first product pair)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Chocolate cookies (second product pair)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Filled rolls (last product pair)
Number of subjects: 421
Study: 616737684

Group type: EXPERIMENTAL
Intervention: REFOCUS intervention
Number of subjects: 37
Study: 36166727

Group type: EXPERIMENTAL
Intervention: Combination nivolumab/ipilimumab (arm A)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Dabrafenib/trametinib (arm B)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Dabrafenib/trametinib (arm C)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Combination nivolumab/ipilimumab (arm D)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Crossover (between arms)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 265
Study: 32656799

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, lenalidomide, and dexamethasone (CRDa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide, thalidomide, and dexamethasone (CTDa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing therapy with lenalidomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 32697308

Group type: EXPERIMENTAL
Intervention: Carboxymethyl cellulose hydrofiber dressing with ionized silver (CMCH‐Ag)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyethylene-polyethylene terephthalate aqua fiber dressing with elementary silver (PPAF‐Ag)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium alginate (CA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium + zinc alginate (CZA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.2% nitrofurazone‐embedded (NF) gauze dressings
Number of subjects: 0
Study: 35197350

Group type: EXPERIMENTAL
Intervention: General Practitioner services in emergency departments (GPEDs)
Number of subjects: 4441349

Group type: COMPARATOR
Intervention: Control group (no GPED services)
Number of subjects: 4441349
Study: 34101953

Group type: EXPERIMENTAL
Intervention: Stratified care
Number of subjects: 333

Group type: COMPARATOR
Intervention: Current practice
Number of subjects: 333
Study: 32699180

Group type: EXPERIMENTAL
Intervention: Dietary sodium restriction (DSR) with a low sodium target of 50 mmol/day
Number of subjects: 13
Study: 34183770

Group type: EXPERIMENTAL
Intervention: Fortified milk enriched with extensively hydrolyzed protein (high protein group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Fortified milk without additional protein (standard protein group)
Number of subjects: 56